Myocardial Infarction Market Report 2025

The myocardial infarction market size has grown strongly in recent years. It will grow from $2.05 billion in 2024 to $2.2 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the introduction of beta-blockers, the establishment of chest pain centers, thrombolytic therapies, personalized medicine approaches, and wearable cardiovascular devices.

The myocardial infarction market size is expected to see strong growth in the next few years. It will grow to $2.94 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to global health initiatives for cardiovascular health, expanded access to reperfusion therapies, RNA therapeutics for cardiovascular diseases, patient-centered care models, focus on microvascular dysfunction, and bioelectronic medicine. Major trends in the forecast period include advancements in cardiovascular imaging, advancements in cardiac surgery techniques, advancements in telemedicine, integration of artificial intelligence in diagnosis, innovation of digital biomarkers for risk prediction, blockchain for healthcare data security, ai-driven drug discovery, and innovations in cardiac rehabilitation technologies.

The anticipated growth of the myocardial infarction market is expected to be driven by an increasing number of smokers. Individuals who engage in smoking, whether through cigarettes, cigars, or pipes, expose themselves to chemicals present in tobacco smoke. These substances have the potential to thicken and clot the blood in veins and arteries, leading to blockages that can result in myocardial infarction. A notable example is the data from the UK-based Office for National Statistics in September 2023, revealing that the segment of the UK population aged 25 to 34 years had the highest percentage of current smokers, accounting for 16.3% or approximately 1.4 million individuals in 2022. This marked an increase from the previous year, when the same age group had a smoking prevalence of 15.8%, encompassing around 1.3 million people. Consequently, the growing number of smokers is a significant factor propelling the growth of the myocardial infarction market.

The increasing prevalence of cardiovascular diseases is anticipated to drive the growth of the myocardial infarction market in the future. Cardiovascular diseases encompass a range of disorders that affect the heart and blood vessels. Drug classes for myocardial infarction are used to manage and treat these conditions, particularly in the aftermath of heart attacks. For example, in September 2024, data published by the British Heart Foundation, a UK-based cardiovascular research charity, indicated that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, comprising about 4 million males and 3.6 million females. These conditions account for around 27% of all deaths in the UK, resulting in over 170,000 fatalities annually, or roughly 480 deaths each day, which translates to one death every three minutes. Thus, the rising incidence of cardiovascular diseases is fueling the growth of the myocardial infarction market.

Major companies in the myocardial infarction market are focused on developing novel drugs, such as anti-inflammatory drugs, for targeted cardiovascular inflammation treatment and to gain a competitive edge in the market. Anti-inflammatory drugs are medications that reduce inflammation, alleviating pain and swelling by targeting the body's immune response. For instance, in June 2023, Agepha Pharma, a Slovakia-based manufacturer of medical products, received FDA approval for its developed drug, Lodoco (colchicine), the first anti-inflammatory drug to target the underlying cause of atherosclerotic cardiovascular disease. Lodoco aims to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients. It can be used alone or with cholesterol-lowering medications. Lodoco, a reformulated low-dose colchicine, demonstrated a 31% reduction in the overall risk of cardiovascular death, myocardial infarction, stroke, or coronary revascularization in a clinical trial.

Major companies in the myocardial infarction market are focused on developing advanced devices that utilize technology, such as SmartAssist dual-sensor technology, to address acute right heart failure and to maximize their profits in the market. SmartAssist dual-sensor technology refers to a system equipped with two sensors designed to gather and monitor advanced metrics in a medical device. For instance, in October 2022, Abiomed, a US-based provider of medical technology, received FDA approval for its Impella RP Flex with SmartAssist. It is implanted via the internal jugular vein; it allows patient mobility and features dual-sensor technology for optimal patient management and weaning. The Impella RP platform includes percutaneous right heart mechanical circulatory support technologies designed for native heart recovery. Impella RP with SmartAssist has received approval from the U.S. FDA for the treatment of right heart failure or decompensation after procedures including left ventricular assist device implantation, myocardial infarction, and heart transplant.

In December 2022, Johnson & Johnson, a leading US-based healthcare products conglomerate, finalized the acquisition of Abiomed for a notable sum of $16.6 billion. This strategic acquisition positions Johnson & Johnson MedTech to integrate heart recovery solutions from Abiomed into its existing Biosense Webster electrophysiology division. By doing so, Johnson & Johnson aims to augment its offerings in the rapidly growing cardiovascular sector. Abiomed, renowned for its pioneering clinical research, specializes in the treatment of acute myocardial infarction, further enriching Johnson & Johnson's comprehensive cardiovascular solutions portfolio.

Major companies operating in the myocardial infarction market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Boehringer Ingelheim GmbH, Merck KGaA, Daiichi Sankyo Co. Ltd., Apotex Inc., Siemens Healthcare Diagnostics Limited, Annexin Pharmaceuticals AB, Heartseed Inc., Par Pharmaceutical Companies Inc., Tenaya Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Acesion Pharma ApS, Applied Therapeutics Inc., Athersys Inc., Cardurion Pharmaceuticals Inc., Verve Therapeutics Inc., Serca Pharmaceuticals AS.

North America was the largest region in the myocardial infarction market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myocardial infarction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Myocardial infarction, commonly known as a heart attack, poses a severe health risk, occurring when the blood flow to a segment of the heart muscle is obstructed, leading to tissue damage or death. This critical condition is often instigated by elevated levels of low-density lipoprotein, hypertension, and tobacco use.

Within the realm of myocardial infarction treatment, various drug classes play pivotal roles in managing and mitigating the condition's impact. These encompass antiplatelet agents, glycoprotein IIB/IIIA inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers, analgesics, and thrombolytics. Antiplatelet agents specifically target the prevention of blood clot formation by inhibiting platelet aggregation. Available in both oral and injectable formulations, these agents are accessible through a diverse range of distribution channels, including hospital pharmacies, retail pharmacies, and online platforms.

The myocardial infarction market research report is one of a series of new reports that provides myocardial infarction market statistics, including myocardial infarction industry global market size, regional shares, competitors with a myocardial infarction market share, detailed myocardial infarction market segments, market trends and opportunities, and any further data you may need to thrive in the myocardial infarction industry. This myocardial infarction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myocardial infarction market consists of sales of heparin, bivalirudin, and enoxaparin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.